PRRT2 and cancer: To demonstrate this application, we cultured MKN45 (a C-MET driven cancer cell line) under light and heavy SILAC conditions (light = kinase inhibitor, heavy = DMSO; K+8 and R+10) and treated cells with either 0.2 μM Staurosporine (ST, protein kinase C [PKC] inhibitor) or 1.0 μM SU11274 (SU, C-MET inhibitor) for 2 h (see Methods) as described by Stokes and colleagues [18].